Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

10812	Companies
234245	Keywords
163041	Articles
125259	Press releases

Home
Companies
Biophytis

PRESS RELEASE

published on 04/08/2024 at 23:04, 2 years 4 months ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. Découvrez les principaux faits marquants et perspectives pour 2024 ainsi que les éléments financiers clés de l'année 2023

Biophytis Biotechnologie Développement Clinique Résultat Annuel Santé
PRESS RELEASE

published on 04/08/2024 at 23:04, 2 years 4 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial
PRESS RELEASE

published on 04/08/2024 at 23:01, 2 years 4 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis annonce ses résultats financiers 2023 et lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone), confirmant son avancement dans le développement de traitements innovants

Biophytis Résultat Annuel Étude Clinique BIO101 Obésité
PRESS RELEASE

published on 04/08/2024 at 23:01, 2 years 4 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs

Financial Results Biophytis 2023 Funding Clinical Programmes
PRESS RELEASE

published on 04/08/2024 at 23:00, 2 years 4 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024

Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation
PRESS RELEASE

published on 04/08/2024 at 23:00, 2 years 4 months ago

Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone). Résultats prometteurs pour traiter la perte musculaire liée à l'obésité. Marché potentiel de 100 milliards de dollars d'ici 2030

Biophytis Étude Clinique BIO101 Obésité Perte Musculaire
BRIEF

published on 04/04/2024 at 23:05, 2 years 4 months ago

Biophytis annonce le succès de son Assemblée Générale du 2 avril 2024

Biophytis Biotechnologie Assemblée Générale Développement Clinique Maladies Liées À L'âge
BRIEF

published on 04/04/2024 at 23:05, 2 years 4 months ago

Biophytis Announces Unanimous Approval in General Meeting

Biophytis Shareholder Approval General Meeting RuvembriTM Age-related Diseases
PRESS RELEASE

published on 04/04/2024 at 23:00, 2 years 4 months ago

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
Biophytis announces all resolutions presented at the combined general meeting on April 2, 2024, have been adopted, including financial delegations. Shareholders' mobilization ensured a quorum of nearly 30%

Shareholders Biophytis General Meeting Resolutions Approval
PRESS RELEASE

published on 04/04/2024 at 23:00, 2 years 4 months ago

RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 2 AVRIL 2024
Biophytis annonce l'adoption de toutes les résolutions lors de son Assemblée Générale Mixte du 2 avril 2024. Les résultats sont disponibles sur leur site. Détails sur les activités et avertissement inclus

Biophytis Développement Biotechnologie Assemblée Générale Résultats

Accesswire

Published on 08/08/2026 at 00:00, 1 day 8 hours ago

Boron One Announces Change of Auditor
Published on 08/07/2026 at 23:15, 1 day 9 hours ago

Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 1 day 9 hours ago

Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 1 day 10 hours ago

UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 1 day 10 hours ago

Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services

View all ACCESSWIRE

EQS Group

Published on 08/09/2026 at 00:01, 8 hours 30 minutes ago

Club Offers for Travel Enthusiasts in Germany
Published on 08/08/2026 at 16:25, 16 hours 5 minutes ago

Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 1 day 9 hours ago

EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 1 day 13 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 1 day 13 hours ago

ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries

Les Echos

Published on 08/07/2026 at 18:54, 1 day 13 hours ago

Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 1 day 13 hours ago

Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 1 day 13 hours ago

Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 1 day 13 hours ago

Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 1 day 14 hours ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026

View all LES ECHOS COMFI WIRE